Clarke, M.Mathew, S.M.Giles, L.C.Pena, A.S.Barr, I.G.Richmond, P.C.Marshall, H.S.2022-06-092022-06-092022Vaccines, 2022; 10(5):699-1-699-122076-393X2076-393Xhttps://hdl.handle.net/2440/135381Obesity can increase the severity of influenza infection. Data are limited regarding immune responses to influenza vaccination in obese children. We aimed to investigate the impact of obesity on quadrivalent influenza vaccine responses in children. Children with obesity (body mass index (BMI) < 95th percentile for age and gender) and children without obesity (BMI < 95th percentile) were enrolled in the study. Blood samples were collected before, 1, and 6 months after influenza vaccination, to measure antibody responses by haemagglutination inhibition (HI) assay. Vaccine immunogenicity outcomes were compared between children with and without obesity. Forty-four children (mean age 13.3 +_ 2.1 years, 18 males and 14 with obesity) completed the 6-month study. More than 90% of the participants with and without obesity had seroprotective antibody titres (HI > 40) at both 1 and 6 months following vaccination for each of the four influenza strains (A/H3N2, A/H1N1, B/(Victoria) and B/(Yamagata)). Influenza-specific geometric mean titres at baseline, 1, and 6 months post-vaccination were similar between children with and without obesity for all influenza vaccine strains. Children with and without obesity have robust, sustained antibody responses over 6 months to the quadrivalent influenza vaccine.enCopyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).influenza avaccinationobesitychildrenadolescentsJournal article10.3390/vaccines100506992022-06-09610924Clarke, M. [0000-0001-9635-8784]Giles, L.C. [0000-0001-9054-9088]Pena, A.S. [0000-0002-6834-4876]Marshall, H.S. [0000-0003-2521-5166]